PMID: 1676070Jan 1, 1991Paper

Duration of action and effect on baroreflex function of the anti-arrhythmic alpha 1 antagonist UK-52,046

The Journal of Pharmacy and Pharmacology
J P SpiersR Wilson

Abstract

The effects of acute and chronic oral administration of UK-52,046 (25 micrograms kg-1) on baroreflex function and its duration of action, were studied in conscious dogs. It was found that UK-52,046 had no effect on blood pressure and heart rate following acute and chronic administration. UK-52,046 shifted the phenylephrine dose response curve to the right, and the PE50 (measure of alpha 1-adrenoceptor antagonism) was increased (P less than 0.05) compared to placebo on day 1 (2, 4, 8 and 24 h) and day 8 (2, 4, 8 and 12 h). The antagonism was increased (P less than 0.05) on day 8 (0, 8 and 12 h) compared with day 1. Evaluation of the effects of UK-52,046 on baroreflex function using phenylephrine to increase blood pressure indicated no significant difference from placebo. It was concluded that at an antiarrhythmic dose, UK-52,046 has no effect on blood pressure, heart rate or baroreflex function. The pressor response curve was shifted to the right indicating a duration of action of at least 12 h on chronic oral administration.

References

Apr 1, 1976·European Journal of Pharmacology·S C Verma, J H McNeill
May 5, 1978·Naunyn-Schmiedeberg's Archives of Pharmacology·J Wagner, O E Brodde
May 5, 1978·Naunyn-Schmiedeberg's Archives of Pharmacology·H J SchümannG Schramm
Jan 1, 1985·Journal of Cardiovascular Pharmacology·D J Sheridan, W Culling
Mar 1, 1988·Journal of Cardiovascular Pharmacology·A H DeeringR G Shanks
Apr 1, 1988·The American Journal of the Medical Sciences·M W ChapleauF M Abboud
Jan 1, 1987·European Journal of Clinical Pharmacology·A H DeeringD W Harron
Jul 1, 1985·Journal of Molecular and Cellular Cardiology·R BrücknerH Scholz
Sep 1, 1987·Circulation Research·P A MunchA M Brown
Sep 1, 1971·The Journal of Pharmacy and Pharmacology·B J AlpsA B Wilson
Jul 1, 1984·Circulation Research·W F Goldman, W R Saum
Feb 1, 1982·Naunyn-Schmiedeberg's Archives of Pharmacology·P T HornL I Goldberg
Jul 12, 1982·Life Sciences·B G Benfey
Jan 1, 1982·Journal of Cardiovascular Pharmacology·W SingletonB N Prichard
Oct 1, 1982·Clinical Pharmacology and Therapeutics·D J SumnerJ L Reid
Jan 1, 1980·The Journal of Clinical Investigation·D J SheridanP B Corr
Jan 1, 1982·European Journal of Clinical Pharmacology·E H Sasso, D T O'Connor

Related Concepts

UK 52046
Adrenergic alpha-Antagonists
Aminoquinolines
Diastolic Blood Pressure
Canis familiaris
Pulse Rate
Phenylephrine Hydrochloride
Pressoreceptors
Tetrahydroisoquinolines

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.